AtriCure Stock News

AtriCure, Inc. (NASDAQ:ATRC) Q1 2020 Earnings Conference Call April 29, 2020, 16:30 ET Company Participants Lynn Lewis - Gilmartin Group Michael Carrel - CEO, P

Oppenheimer analyst Suraj Kalia maintained a Buy rating on Atricure (ATRC – Research Report) yesterday and set a price target

In a report released yesterday, Marie Thibault from BTIG reiterated a Buy rating on Atricure ( ATRC – Research Report ), with a price target of $45.00 . The company’s shares closed last Wednesday

AtriCure (ATRC) delivered earnings and revenue surprises of 5.26% and 0.27%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

AtriCure (ATRC) delivered earnings and revenue surprises of 5.26% and 0.27%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

MASON, Ohio (AP) _ AtriCure Inc. (ATRC) on Wednesday reported a loss of $16.4 million in its first quarter. On a per-share basis, the Mason, Ohio-based company said it had a loss of 42 cents. Losses,

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced first quarter 2020 financial results.

Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs April 28.) * AstraZeneca plc (NYSE: AZN) * Arcturus Therapeu

Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable Sacral Neuromodulation ("SNM") devices for the treatment

AtriCure reports Q1 EPS (42c), consensus (41c) ATRC

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs April 28.) AstraZeneca plc (NYSE:...

Untreated heart attacks negative for Abiomed, says Piper Sandler Piper Sandler ABMD BSX MDT ATRC

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participat